Ryan Allway May 9th, 2023 Psychedelics, Top Story MindBio clinical trial published in Peer Reviewed Paper Biological Psychiatry First of 8 significant publications on LSD-Microdosing from a Phase 1 clinical trial Phase 1 Clinical trial produced outstanding mood responses in healthy participants MindBio is developing a Microdosing treatment protocol... Read more
Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Public Offering for Clearmind Medicine Inc. (NASDAQ: CMND)
April 10, 2023
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Silo Pharma Announces Stock Repurchase Program
January 31, 2023
Ryan Allway January 31st, 2023 News, Top News ENGLEWOOD CLIFFS, NJ, Jan. 31, 2023 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire... Read more
BioHarvest Sciences Inc. Appoints Dr. George Garibaldi to Its Scientific Board of Advisors
January 17, 2023
Ryan Allway January 17th, 2023 News, Top News Dr. Garibaldi’s 40 years of experience brings industry-leading pharmaceuticals development expertise to the Scientific Board of Advisors. His appointment demonstrates the company’s resolve to leverage its biotechnology platform for enabling drugs development. Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – January... Read more
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
December 20, 2022
Phase 2 clinical trial planned to start in H1 2023San Diego, California, December 20, 2022 — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, today announced that the U.S. Food and Drug Administration (“FDA”) has given... Read more
Novigenix announces first closing of its $20M Series B
November 15, 2022
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2022 RESULTS AND ANNOUNCES APPOINTMENT OF DR SEUFER-WASSERTHAL AS PRESIDENT AND CEO
November 3, 2022
Ryan Allway November 3rd, 2022 News, Top News CALGARY, AB AND MOUNTAIN VIEW, CA, Nov. 3, 2022 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, has released its financial and operating results... Read more
Ryan Allway August 18th, 2022 News, Top News Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – August 18, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) has announced the first multimedia campaign for VINIA™ in the USA, Phase 1. The company is scaling up... Read more
Ryan Allway July 18th, 2022 News, Top News Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – July 18, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) “) is pleased to announce that its common shares are now trading on the OTCQB® Venture Market under... Read more
BioHarvest Sciences Inc. Reports Strong Q2 2022 Results with Major Achievements on All Fronts
July 5, 2022
Ryan Allway July 5th, 2022 News, Top News VINIA® sales orders reached a record high of USD 947k representing 99% growth compared to Q2 2021 and 24% growth compared to Q1 2022 BioHarvest reiterates guidance for year-on-year sales orders growth of 2.5-3.5X to reach USD 5M – 7M Started... Read more
